SR 271425: structure in first source
ID Source | ID |
---|---|
PubMed CID | 9909677 |
CHEMBL ID | 434812 |
SCHEMBL ID | 107609 |
MeSH ID | M0354716 |
Synonym |
---|
CHEMBL434812 , |
NCGC00247953-01 |
sw-271425 |
155990-20-8 |
115755x1l7 , |
win 71425 |
unii-115755x1l7 |
sw-71425 |
win-71425 |
sr 271425 |
formamide, n-((1-((2-(diethylamino)ethyl)amino)-7-methoxy-9-oxo-9h-thioxanthen-4-yl)methyl)- |
sr271425 |
cas-155990-20-8 |
dtxsid8047347 , |
NCGC00253949-01 |
dtxcid6027347 |
tox21_300233 |
sr-271425 |
SCHEMBL107609 |
GWLFIMOOGVXSMZ-UHFFFAOYSA-N , |
n-[[1-[[2-(diethylamino) ethyl]amino]-7-methoxy-9-oxothioxanthen-4-yl]-methyl ]formamide |
n-[[1-[[2-(diethylamino)ethyl]amino]-7-methoxy-9-oxothioxanthen-4-yl]methyl]formamide |
n-[[1-[2-(diethylamino)ethylamino]-7-methoxy-9-oxothioxanthen-4-yl]methyl]formamide |
Q27251267 |
bdbm50471786 |
n-[(1-{[2-(diethylamino)ethyl]amino}-7-methoxy-9-oxo-9h-thioxanthen-4-yl)methyl]formamide |
AKOS040749554 |
Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
acetylcholinesterase | Homo sapiens (human) | Potency | 72.8772 | 0.0025 | 41.7960 | 15,848.9004 | AID1347395; AID1347397; AID1347398 |
GLI family zinc finger 3 | Homo sapiens (human) | Potency | 1.4699 | 0.0007 | 14.5928 | 83.7951 | AID1259369; AID1259392 |
AR protein | Homo sapiens (human) | Potency | 28.5245 | 0.0002 | 21.2231 | 8,912.5098 | AID1259243; AID1259247; AID743036; AID743042; AID743053; AID743054; AID743063 |
caspase 7, apoptosis-related cysteine protease | Homo sapiens (human) | Potency | 61.1306 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
estrogen receptor 2 (ER beta) | Homo sapiens (human) | Potency | 68.5896 | 0.0006 | 57.9133 | 22,387.1992 | AID1259377; AID1259394 |
nuclear receptor subfamily 1, group I, member 3 | Homo sapiens (human) | Potency | 1.7343 | 0.0010 | 22.6508 | 76.6163 | AID1224838; AID1224893 |
progesterone receptor | Homo sapiens (human) | Potency | 43.2771 | 0.0004 | 17.9460 | 75.1148 | AID1346795 |
glucocorticoid receptor [Homo sapiens] | Homo sapiens (human) | Potency | 21.5775 | 0.0002 | 14.3764 | 60.0339 | AID720691; AID720692; AID720719 |
retinoic acid nuclear receptor alpha variant 1 | Homo sapiens (human) | Potency | 61.5361 | 0.0030 | 41.6115 | 22,387.1992 | AID1159552; AID1159555 |
retinoid X nuclear receptor alpha | Homo sapiens (human) | Potency | 9.4755 | 0.0008 | 17.5051 | 59.3239 | AID1159527; AID1159531 |
estrogen-related nuclear receptor alpha | Homo sapiens (human) | Potency | 27.3920 | 0.0015 | 30.6073 | 15,848.9004 | AID1224841; AID1224842; AID1224848; AID1224849; AID1259401; AID1259403 |
farnesoid X nuclear receptor | Homo sapiens (human) | Potency | 25.9283 | 0.3758 | 27.4851 | 61.6524 | AID743217; AID743220; AID743239 |
pregnane X nuclear receptor | Homo sapiens (human) | Potency | 61.1306 | 0.0054 | 28.0263 | 1,258.9301 | AID1346982 |
estrogen nuclear receptor alpha | Homo sapiens (human) | Potency | 8.9394 | 0.0002 | 29.3054 | 16,493.5996 | AID1259244; AID1259248; AID743069; AID743075; AID743077; AID743078; AID743079; AID743080; AID743091 |
peroxisome proliferator-activated receptor delta | Homo sapiens (human) | Potency | 15.4845 | 0.0010 | 24.5048 | 61.6448 | AID743215 |
peroxisome proliferator activated receptor gamma | Homo sapiens (human) | Potency | 17.7341 | 0.0010 | 19.4141 | 70.9645 | AID743140; AID743191 |
vitamin D (1,25- dihydroxyvitamin D3) receptor | Homo sapiens (human) | Potency | 43.6412 | 0.0237 | 23.2282 | 63.5986 | AID743223 |
caspase-3 | Homo sapiens (human) | Potency | 61.1306 | 0.0133 | 26.9810 | 70.7614 | AID1346978 |
aryl hydrocarbon receptor | Homo sapiens (human) | Potency | 17.4605 | 0.0007 | 23.0674 | 1,258.9301 | AID743085; AID743122 |
cytochrome P450, family 19, subfamily A, polypeptide 1, isoform CRA_a | Homo sapiens (human) | Potency | 38.5708 | 0.0017 | 23.8393 | 78.1014 | AID743083 |
thyroid stimulating hormone receptor | Homo sapiens (human) | Potency | 67.2985 | 0.0016 | 28.0151 | 77.1139 | AID1259385; AID1259395 |
nuclear factor of kappa light polypeptide gene enhancer in B-cells 1 (p105), isoform CRA_a | Homo sapiens (human) | Potency | 12.2998 | 19.7391 | 45.9784 | 64.9432 | AID1159509 |
Caspase-7 | Cricetulus griseus (Chinese hamster) | Potency | 30.6379 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
caspase-3 | Cricetulus griseus (Chinese hamster) | Potency | 30.6379 | 0.0067 | 23.4960 | 68.5896 | AID1346980 |
thyroid hormone receptor beta isoform 2 | Rattus norvegicus (Norway rat) | Potency | 24.8126 | 0.0003 | 23.4451 | 159.6830 | AID743065; AID743067 |
nuclear factor erythroid 2-related factor 2 isoform 1 | Homo sapiens (human) | Potency | 34.3762 | 0.0006 | 27.2152 | 1,122.0200 | AID743202 |
Voltage-dependent calcium channel gamma-2 subunit | Mus musculus (house mouse) | Potency | 1.9331 | 0.0015 | 57.7890 | 15,848.9004 | AID1259244 |
Cellular tumor antigen p53 | Homo sapiens (human) | Potency | 7.5844 | 0.0023 | 19.5956 | 74.0614 | AID651631; AID720552 |
Glutamate receptor 2 | Rattus norvegicus (Norway rat) | Potency | 1.9331 | 0.0015 | 51.7393 | 15,848.9004 | AID1259244 |
ATPase family AAA domain-containing protein 5 | Homo sapiens (human) | Potency | 35.2915 | 0.0119 | 17.9420 | 71.5630 | AID651632; AID720516 |
Ataxin-2 | Homo sapiens (human) | Potency | 27.3060 | 0.0119 | 12.2221 | 68.7989 | AID651632 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
---|---|---|---|---|---|---|---|
DNA topoisomerase 2-alpha | Homo sapiens (human) | EC50 (µMol) | 480.0000 | 0.7200 | 1.2900 | 3.0000 | AID211289 |
DNA topoisomerase 2-beta | Homo sapiens (human) | EC50 (µMol) | 480.0000 | 0.7200 | 1.2900 | 3.0000 | AID211289 |
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] |
Assay ID | Title | Year | Journal | Article |
---|---|---|---|---|
AID136055 | In vivo antitumor activity in mice implanted with murine pancreatic adenocarcinoma 03, T/C value (total/control) | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives. |
AID133779 | Maximum tolerated dose administarted iv (mg/kg) to mice | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives. |
AID46155 | In vitro evaluation for intercalating potency by using calf thymus DNA in ethidium bromide displacement assay | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives. |
AID134904 | The long term cures (LTC) value is the number of mice in a group with no palpable tumor. | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives. |
AID211289 | In vitro evaluation for inhibitor of human topoisomerase II from HeLa cells. | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives. |
AID134219 | The log cell kill of tumor-bearing mice, based on tumor growth delay. | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives. |
AID150540 | In vitro cytotoxicity measured by quantifying clonogenic survival in soft agar following a 1-hour transient exposure of p388 mouse leukemia cells. | 1998 | Journal of medicinal chemistry, Sep-10, Volume: 41, Issue:19 | Synthesis and antitumor activity of 4-aminomethylthioxanthenone and 5-aminomethylbenzothiopyranoindazole derivatives. |
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Timeframe | Studies, This Drug (%) | All Drugs % |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 2 (25.00) | 18.2507 |
2000's | 6 (75.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 0 (0.00) | 2.80 |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.12) All Compounds (24.57) |
Publication Type | This drug (%) | All Drugs (%) |
---|---|---|
Trials | 4 (50.00%) | 5.53% |
Reviews | 0 (0.00%) | 6.00% |
Case Studies | 0 (0.00%) | 4.05% |
Observational | 0 (0.00%) | 0.25% |
Other | 4 (50.00%) | 84.16% |
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |